303 related articles for article (PubMed ID: 12482972)
1. Proteolytic cleavage of MLL generates a complex of N- and C-terminal fragments that confers protein stability and subnuclear localization.
Hsieh JJ; Ernst P; Erdjument-Bromage H; Tempst P; Korsmeyer SJ
Mol Cell Biol; 2003 Jan; 23(1):186-94. PubMed ID: 12482972
[TBL] [Abstract][Full Text] [Related]
2. Taspase1: a threonine aspartase required for cleavage of MLL and proper HOX gene expression.
Hsieh JJ; Cheng EH; Korsmeyer SJ
Cell; 2003 Oct; 115(3):293-303. PubMed ID: 14636557
[TBL] [Abstract][Full Text] [Related]
3. Leukemia proto-oncoprotein MLL is proteolytically processed into 2 fragments with opposite transcriptional properties.
Yokoyama A; Kitabayashi I; Ayton PM; Cleary ML; Ohki M
Blood; 2002 Nov; 100(10):3710-8. PubMed ID: 12393701
[TBL] [Abstract][Full Text] [Related]
4. The mixed lineage leukemia (MLL) protein involved in 11q23 translocations contains a domain that binds cruciform DNA and scaffold attachment region (SAR) DNA.
Broeker PL; Harden A; Rowley JD; Zeleznik-Le N
Curr Top Microbiol Immunol; 1996; 211():259-68. PubMed ID: 8585957
[TBL] [Abstract][Full Text] [Related]
5. The HRX proto-oncogene product is widely expressed in human tissues and localizes to nuclear structures.
Butler LH; Slany R; Cui X; Cleary ML; Mason DY
Blood; 1997 May; 89(9):3361-70. PubMed ID: 9129043
[TBL] [Abstract][Full Text] [Related]
6. The amino terminus targets the mixed lineage leukemia (MLL) protein to the nucleolus, nuclear matrix and mitotic chromosomal scaffolds.
Caslini C; Alarcòn AS; Hess JL; Tanaka R; Murti KG; Biondi A
Leukemia; 2000 Nov; 14(11):1898-908. PubMed ID: 11069025
[TBL] [Abstract][Full Text] [Related]
7. Binding to nonmethylated CpG DNA is essential for target recognition, transactivation, and myeloid transformation by an MLL oncoprotein.
Ayton PM; Chen EH; Cleary ML
Mol Cell Biol; 2004 Dec; 24(23):10470-8. PubMed ID: 15542854
[TBL] [Abstract][Full Text] [Related]
8. 11q23 translocations split the "AT-hook" cruciform DNA-binding region and the transcriptional repression domain from the activation domain of the mixed-lineage leukemia (MLL) gene.
Zeleznik-Le NJ; Harden AM; Rowley JD
Proc Natl Acad Sci U S A; 1994 Oct; 91(22):10610-4. PubMed ID: 7938000
[TBL] [Abstract][Full Text] [Related]
9. The localization of the HRX/ALL1 protein to specific nuclear subdomains is altered by fusion with its eps15 translocation partner.
Rogaia D; Grignani F; Carbone R; Riganelli D; LoCoco F; Nakamura T; Croce CM; Di Fiore PP; Pelicci PG
Cancer Res; 1997 Mar; 57(5):799-802. PubMed ID: 9041173
[TBL] [Abstract][Full Text] [Related]
10. MLL repression domain interacts with histone deacetylases, the polycomb group proteins HPC2 and BMI-1, and the corepressor C-terminal-binding protein.
Xia ZB; Anderson M; Diaz MO; Zeleznik-Le NJ
Proc Natl Acad Sci U S A; 2003 Jul; 100(14):8342-7. PubMed ID: 12829790
[TBL] [Abstract][Full Text] [Related]
11. ELL-associated factor 2 (EAF2), a functional homolog of EAF1 with alternative ELL binding properties.
Simone F; Luo RT; Polak PE; Kaberlein JJ; Thirman MJ
Blood; 2003 Mar; 101(6):2355-62. PubMed ID: 12446457
[TBL] [Abstract][Full Text] [Related]
12. Domains with transcriptional regulatory activity within the ALL1 and AF4 proteins involved in acute leukemia.
Prasad R; Yano T; Sorio C; Nakamura T; Rallapalli R; Gu Y; Leshkowitz D; Croce CM; Canaani E
Proc Natl Acad Sci U S A; 1995 Dec; 92(26):12160-4. PubMed ID: 8618864
[TBL] [Abstract][Full Text] [Related]
13. Chimeric MLL products with a Ras binding cytoplasmic protein AF6 involved in t(6;11) (q27;q23) leukemia localize in the nucleus.
Joh T; Yamamoto K; Kagami Y; Kakuda H; Sato T; Yamamoto T; Takahashi T; Ueda R; Kaibuchi K; Seto M
Oncogene; 1997 Oct; 15(14):1681-7. PubMed ID: 9349501
[TBL] [Abstract][Full Text] [Related]
14. Cooperativity in transcription factor binding to the coactivator CREB-binding protein (CBP). The mixed lineage leukemia protein (MLL) activation domain binds to an allosteric site on the KIX domain.
Goto NK; Zor T; Martinez-Yamout M; Dyson HJ; Wright PE
J Biol Chem; 2002 Nov; 277(45):43168-74. PubMed ID: 12205094
[TBL] [Abstract][Full Text] [Related]
15. The oncogenic capacity of HRX-ENL requires the transcriptional transactivation activity of ENL and the DNA binding motifs of HRX.
Slany RK; Lavau C; Cleary ML
Mol Cell Biol; 1998 Jan; 18(1):122-9. PubMed ID: 9418860
[TBL] [Abstract][Full Text] [Related]
16. Biphasic MLL takes helm at cell cycle control: implications in human mixed lineage leukemia.
Liu H; Takeda S; Cheng EH; Hsieh JJ
Cell Cycle; 2008 Feb; 7(4):428-35. PubMed ID: 18235233
[TBL] [Abstract][Full Text] [Related]
17. Structure of AF3p21, a new member of mixed lineage leukemia (MLL) fusion partner proteins-implication for MLL-induced leukemogenesis.
Sano K
Leuk Lymphoma; 2001 Aug; 42(4):595-602. PubMed ID: 11697487
[TBL] [Abstract][Full Text] [Related]
18. LCX, leukemia-associated protein with a CXXC domain, is fused to MLL in acute myeloid leukemia with trilineage dysplasia having t(10;11)(q22;q23).
Ono R; Taki T; Taketani T; Taniwaki M; Kobayashi H; Hayashi Y
Cancer Res; 2002 Jul; 62(14):4075-80. PubMed ID: 12124344
[TBL] [Abstract][Full Text] [Related]
19. The small oligomerization domain of gephyrin converts MLL to an oncogene.
Eguchi M; Eguchi-Ishimae M; Greaves M
Blood; 2004 May; 103(10):3876-82. PubMed ID: 14751928
[TBL] [Abstract][Full Text] [Related]
20. A carboxy-terminal domain of ELL is required and sufficient for immortalization of myeloid progenitors by MLL-ELL.
DiMartino JF; Miller T; Ayton PM; Landewe T; Hess JL; Cleary ML; Shilatifard A
Blood; 2000 Dec; 96(12):3887-93. PubMed ID: 11090074
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
